NEW YORK, Jan. 22 - Millennium Pharmaceuticals on Tuesday said that fourth-quarter losses widened as revenue fell and spending on new drug development increased.

Net loss for the quarter ended Dec. 31grew by 79 percent to $66.97 million, or 30 cents a share, from $37.49 million, or 18 cents, in the same period last year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.